A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

Cell Reports
Paul SavageJiannis Ragoussis

Abstract

Therapies targeting epidermal growth factor receptor (EGFR) have variable and unpredictable responses in breast cancer. Screening triple-negative breast cancer (TNBC) patient-derived xenografts (PDXs), we identify a subset responsive to EGFR inhibition by gefitinib, which displays heterogeneous expression of wild-type EGFR. Deep single-cell RNA sequencing of 3,500 cells from an exceptional responder identified subpopulations displaying distinct biological features, where elevated EGFR expression was significantly enriched in a mesenchymal/stem-like cellular cluster. Sorted EGFRhi subpopulations exhibited enhanced stem-like features, including ALDH activity, sphere-forming efficiency, and tumorigenic and metastatic potential. EGFRhi cells gave rise to EGFRhi and EGFRlo cells in primary and metastatic tumors, demonstrating an EGFR-dependent expansion and hierarchical state transition. Similar tumorigenic EGFRhi subpopulations were identified in independent PDXs, where heterogeneous EGFR expression correlated with gefitinib sensitivity. This provides new understanding for an EGFR-dependent hierarchy in TNBC and for patient stratification for therapeutic intervention.

Citations

Apr 25, 2018·Drug Metabolism and Personalized Therapy·Sujit Nair, Adrián LLerena
Oct 12, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·I A Voutsadakis
Jul 28, 2020·Advanced Science·Lina ZhaoBaowei Jiao
Apr 1, 2019·Nature Metabolism·George A Calin, Barbara Pardini
Oct 12, 2018·Oncogene·H Rudolf de BoerMarcel A T M van Vugt
Jun 19, 2019·Nature Methods·Christopher S McGinnisZev J Gartner
Nov 30, 2018·Nature Cell Biology·Devon A LawsonZena Werb
Apr 2, 2020·Briefings in Functional Genomics·Ziwei WangQuan Zou
May 21, 2020·Molecular Cancer Therapeutics·Alexander RauRoland E Kontermann
May 31, 2019·Cancer Research·Arvind S MerBenjamin Haibe-Kains
Feb 11, 2021·Trends in Cancer·Aritro Nath, Andrea H Bild
Nov 13, 2020·Reports of Biochemistry & Molecular Biology·Forough Abdollahzadeh, Foroogh Nejatollahi
Oct 28, 2020·Journal of Mammary Gland Biology and Neoplasia·Emma D WrennKevin J Cheung
Feb 22, 2021·Genes, Chromosomes & Cancer·Ulrich PfistererThoas Fioretos
Mar 28, 2021·NPJ Breast Cancer·Vanessa Y C SungMorag Park
Apr 4, 2021·Cancer Discovery·L Nicolas Gonzalez CastroMario L Suvà
Aug 19, 2021·Protein & Cell·Yanmeng LiFan Bai
Oct 3, 2021·Genome Research·Dalia BarkleyItai Yanai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
K GelmonS Verma
Annals of Oncology : Official Journal of the European Society for Medical Oncology
B CorkeryN O'Donovan
Journal of Cancer Research and Clinical Oncology
Nami YamashitaYoshihiko Maehara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Marc DamelinScott J Dylla
© 2022 Meta ULC. All rights reserved